{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "27513345",
  "DateCompleted": {
    "Year": "2017",
    "Month": "05",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2017",
    "Month": "05",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2016",
        "Month": "08",
        "Day": "11"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1159/000447392"
    ],
    "Journal": {
      "ISSN": "1421-9832",
      "JournalIssue": {
        "Volume": "232 Suppl 1",
        "PubDate": {
          "Year": "2016"
        }
      },
      "Title": "Dermatology (Basel, Switzerland)",
      "ISOAbbreviation": "Dermatology"
    },
    "ArticleTitle": "Ingenol Mebutate vs. Daylight Photodynamic Therapy in a Kidney Transplant Recipient.",
    "Pagination": {
      "StartPage": "20",
      "EndPage": "23",
      "MedlinePgn": "20-3"
    },
    "Abstract": {
      "AbstractText": [
        "We present the case of a 73-year-old male patient who had received a first renal transplant at 36 years and a second one at the age of 55 years. He is currently under immunosuppression with everolimus 2.5 mg/day and prednisone 5 mg/day. The patient presented with multiple actinic keratoses on both cheeks and the forehead and received treatment by ingenol mebutate 150 \u00b5g/g gel daily on 3 consecutive days on his right cheek and methyl aminolevulinate (MAL) photodynamic therapy activated by daylight (MAL-dPDT) on the forehead and the left cheek. MAL-dPDT treatment proved a feasible, repeatable, physician-directed method of treating field cancerization with limited morbidity for a period of 6 days. Treatment with ingenol mebutate gel was a feasible, possibly self-directed method of treating field cancerization with limited morbidity for 10 days in this immunosuppressed patient. Both treatments showed similar efficacy. At the time of treatment, the MAL daylight PDT ran at 3 times the cost of ingenol mebutate gel."
      ],
      "CopyrightInformation": "\u00a9 2016 S. Karger AG, Basel."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Dermatology and Venerology, Geneva University Hospitals, Geneva, Switzerland."
          }
        ],
        "LastName": "M\u00fchlst\u00e4dt",
        "ForeName": "Michael",
        "Initials": "M"
      }
    ],
    "PublicationTypeList": [
      "Case Reports",
      "Comparative Study",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Dermatology",
    "NlmUniqueID": "9203244",
    "ISSNLinking": "1018-8665"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "3-ingenyl angelate"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Diterpenes"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Photosensitizing Agents"
    },
    {
      "RegistryNumber": "585NM85KYM",
      "NameOfSubstance": "methyl 5-aminolevulinate"
    },
    {
      "RegistryNumber": "88755TAZ87",
      "NameOfSubstance": "Aminolevulinic Acid"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "analogs & derivatives"
      ],
      "DescriptorName": "Aminolevulinic Acid"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Carcinogenesis"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Carcinoma, Basal Cell"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Carcinoma, Squamous Cell"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Diterpenes"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Face"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Keratosis, Actinic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Kidney Transplantation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Photochemotherapy"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Photosensitizing Agents"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Skin Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Transplant Recipients"
    }
  ]
}